Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Valproic Acid”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 451 records · Page 25Linked to original sources

Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells.

Pathogenesis of prostate cancer is paralleled by aberrant transcriptional regulation which involves gene silencing by histone deacetylases. In cancer cells, inhibitors of histone deacetylases such as valproic acid can act as differentiation agents which relieve pro-apoptotic factors from transcriptional repression. We investigated the potential of the well-tolerated anticonvulsant valproic acid in prostate cancer cell line LNCaP and analyzed the activation of pro-apoptotic factors and resulting apoptosis. We used real time RT-PCR to quantify the mRNA expression of prostate-specific antigen, prostate-derived Ets transcription factor, tissue inhibitor of matrix metalloproteinase-3 and insulin-like growth factor binding protein-3. An automated sandwich-ELISA was used to measure secretion of prostate-specific antigen in conditioned cell culture media of LNCaP prostate cancer cells. Apoptotic cells were detected cytochemically and by applying immunocytochemistry. Activity of histone deacetylases in nuclear extracts was measured with a colorimetric assay kit. Valproic acid treatment caused a marked inhibition of histone deacetylases activity. Expression of prostate-derived Ets transcription factor and consequently prostate-specific antigen were down-regulated to basal levels in LNCaP cells. Pro-apoptotic factor caspase-3, tissue inhibitor of matrix metalloproteinase-3 and insulin-like growth factor binding protein-3 were up-regulated resulting in apoptosis of tumor cells. Valproic acid mediates marked effects on the expression of genes relevant in proliferation and apoptosis. Our study provides strong evidence that prostate cancer may benefit particularly from anti-proliferative stimuli from this well established drug.

Apoptosis↗

Development and validation of a sensitive assay of valproic acid in human plasma by high-performance liquid chromatography without prior derivatization.

Sensitive and selective determination of valproic acid in plasma by high-performance liquid chromatography (HPLC) is usually achieved with pre-column derivatization. In the present work, the derivatization is omitted due to using a simple but highly selective plasma extraction procedure and an optimized chromatographic condition. Valproic acid and the internal standard octanoic acid were extracted from plasma samples with n-hexane under acidic condition followed by back-extraction into diluted triethylamine. Chromatography was performed on a CN column (250 x 4.6 mm, 5 microm) under isocratic elution with acetonitrile-40 mM aqueous sodium dihydrogen phosphate (30:70, v/v), pH 3.5. Detection was made at 210 nm and analyses were run at a flow-rate of 1 ml/min. The method was specific and sensitive with a quantification limit of 1.25 microg/ml and a detection limit of 0.1 microg/ml in plasma. The mean absolute recovery for valproic acid using the present plasma extraction procedure was 75.8%. The intra- and inter-day coefficient of variation and percent error values of the assay method were all in acceptable range. Calibration curves were linear (r>0.999) from 1.25 to 320 microg/ml in plasma.

Calibration↗

Reversible altered consciousness with brain atrophy caused by valproic acid.

A 5-year-old female developed alteration of consciousness during 3 days of long-term treatment with valproic acid for localization-related epilepsy. Computed tomography revealed cerebral atrophy, and electroencephalography presented slow background activity. Consciousness cleared only 12 hours after valproic acid was discontinued, and normal electroencephalography results were evident 1 week later. Cerebral atrophy was nonexistent 2 months later. This rapidly developing but reversible alteration of consciousness in parallel with brain atrophy is recognized as a rare idiosyncratic adverse effect of valproic acid.

Atrophy↗

Rapid gas chromatographic assay for monitoring valproic acid and valpromide in plasma.

A gas chromatographic (GC) method for monitoring valproic acid and valpromide in plasma was developed. The procedure involved a single solvent extraction of drugs from acidified plasma samples, followed by a GC injection of the organic phase. This rapid, sensitive, specific, and reproducible method is a key factor in pharmacokinetic and stability studies of valpromide. Pharmacokinetic application of the new GC method is presented by a simultaneous plasma monitoring of valpromide and valproic acid levels obtained after intravenous administration of valpromide to a dog.

Chromatography, Gas↗

Pancreatitis induced by valproic acid: report of a case.

A 22-year-old woman with intellectual impairment, who had been taking valproic acid continuously for 19 years since being diagnosed with epiloia at the age of 3 years, presented to our hospital following the sudden development of epigastric pain. An abdominal computed tomography scan revealed acute exacerbation of chronic pancreatitis. Conservative treatment was initiated, despite which the pancreatitis became exacerbated, necessitating resection of the pancreatic head and duodenum. Histological examination of the resected specimens revealed a large number of pancreatic calculi in the main pancreatic duct, suggesting chronic pancreatitis with fibrosis at the periphery. The incidence of pancreatitis developing in association with valproic acid is unclear; however, only 40 such cases have been reported in the English literature. Most of the patients previously described presented with acute pancreatitis in the initial stage. However, the clinical course of our patient, with acute exacerbation following a relatively chronic course, was different from those previously described, suggesting the presence of chronic pancreatitis related to valproic acid.

Adult↗

Valproic acid for the treatment of social anxiety disorder.

The aim of the study was to examine the efficacy of valproic acid in participants with social anxiety disorder. Following a 2-week single-blind, placebo run-in period, 17 participants were enrolled in a 12-week open flexible-dose trial of valproic acid (500-2500 mg). The primary outcome measures were the mean change from baseline in the Liebowitz Social Anxiety Scale (LSAS) total score and responder status [defined as a Clinical Global Impression of Improvement score (CGI-I) < or =2]. Social anxiety symptoms as measured by the LSAS and CGI-I scores significantly improved with treatment. The mean reduction in the LSAS was 21.3 points in the last visit carried forward analysis and 19.1 points for the completer analysis, with 41.1% and 46.6% participants, respectively, achieving responder status. The results from this open-label trial suggest the potential efficacy of valproic acid for the treatment of social anxiety disorder. Placebo-controlled trials are indicated to confirm these findings.

Adult↗

Congenital malformations associated with maternal use of valproic acid.

Two children born with birth defects after intrauterine exposure to valproic acid are reported. The mothers took the drug throughout pregnancy as sole treatment for primary generalized epilepsy. The first baby showed facial dysmorphism, arachnodactyly and triphalangeal thumbs. The second had facial dysmorphism, severe laryngeal hypoplasia, tracheomalacia and an aberrant innominate artery that caused tracheal compression. A left superior vena cava, abnormal pulmonary lobulation, and unilateral hydronephrosis were also found at autopsy. Valproic acid has probable teratogenic potential in humans but the number of reported cases is few and the spectrum of anomalies is broad so it is not possible to delineate a definite fetal valproate syndrome.

Abnormalities, Drug-Induced↗

Aplasia cutis congenita of the scalp in an infant exposed to valproic acid in utero.

We report a newborn with isolated aplasia cutis congenita of the scalp whose mother was treated with valproic acid during pregnancy. Aplasia cutis congenita has been described in infants exposed in utero to antithyroid drugs, but has not been related to other tetratogenic agents. Fetal exposure to valproic acid is known to increase the risks of spina bifida and other midline defects. Interestingly, aplasia cutis congenita of the scalp is regarded as a cutaneous marker for neural dysraphism. However, this defect of the scalp and valproic acid intake during pregnancy may be a random association and similar observations are needed to suggest causality.

Abnormalities, Drug-Induced↗

Valproic Acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts.

PURPOSE: To develop novel orthotopic xenograft models of medulloblastoma in severe combined immunodeficient mice and to evaluate the in vivo antitumor efficacy of valproic acid. EXPERIMENTAL DESIGN: Orthotopic xenografts were developed by injecting 10(3) to 10(5) tumor cells from four medulloblastoma cell lines (D283-MED, DAOY, MHH-MED-1, and MEB-MED-8A) into the right cerebellum of severe combined immunodeficient mice. Animals were then examined for reproducibility of tumorigenicity, cell number-survival time relationship, and histopathologic features. Tumor growth was monitored in vivo by serially sectioning the xenograft brains at 2, 4, 6, and 8 weeks postinjection. Valproic acid treatment, administered at 600 microg/h for 2 weeks via s.c. osmotic minipumps, was initiated 2 weeks after injection of 10(5) medulloblastoma cells, and treated and untreated animals were monitored for differences in survival. Changes in histone acetylation, proliferation, apoptosis, differentiation, and angiogenesis in xenografts were also evaluated. RESULTS: Tumorigenicity was maintained at 100% in D283-MED, DAOY, and MHH-MED-1 cell lines. These cerebellar xenografts displayed histologic features and immunohistochemical profiles (microtubule-associated protein 2, glial fibrillary acidic protein, and vimentin) similar to human medulloblastomas. Animal survival time was inversely correlated with injected tumor cell number. Treatment with valproic acid prolonged survival time in two (D283-MED and MHH-MED-1) of the three models and was associated with induction of histone hyperacetylation, inhibition of proliferation and angiogenesis, and enhancement of apoptosis and differentiation. CONCLUSION: We have developed intracerebellar orthotopic models that closely recapitulated the biological features of human medulloblastomas and characterized their in vivo growth characteristics. Valproic acid treatment of these xenografts showed potent in vivo anti-medulloblastoma activity. These xenograft models should facilitate the understanding of medulloblastoma pathogenesis and future preclinical evaluation of new therapies against medulloblastoma.

Animals↗

Effect of valproic acid on spike and wave discharges in patients with absence seizures.

Twenty-five patients with absence seizures were treated with valproic acid in doses from 17 to 62.5 mg per kilogram per day. Nineteen patients experienced reduction of spike and wave discharges; in 11 it was greater than 75 percent. Twenty-one patients had a reduction of the total time of spike and wave discharge. Four patients had increase of spike and wave discharges. Nineteen patients had fewer absence seizures. There was no correlation between plasma concentration of valproic acid and EEG change, but clinical improvement occurred when plasma levels of valproic acid reached 50 to 60 microgram per milliliter.

Adolescent↗

[The effect of valproic acid on sleep structure and ethanol consumption in rats with various types of individual reactivity before and after stress exposure].

The influence of valproic acid on sleep structure and alcohol motivation was studied in pretyped rats prior and following REM sleep deprivation. During EEG recording of wake-sleep cycle valporoic acid was shown to produce hypnotic action dependent on drug dosage in high active and low active animals. There was also shown that following REM sleep deprivation low active animals significantly reduced ethanol consumption under valproic acid influence. It seems likely from the results obtained that valproic acid could be used as hypnotic and antialcoholic drug.

Alcohol Drinking↗

Changes in pharmacokinetics of valproic acid in guinea pigs from birth to maturity.

Pharmacokinetic variations of valproic acid in guinea pigs from birth to maturity were investigated. Male guinea pigs were classified into three groups according to age, and each group was further divided into two to three subgroups. The suckling group included three subgroups of 3, 6, and 10 days of age; the juvenile group, three subgroups of 14, 21, and 28 days of age; and the adult group, two subgroups of 42 and 56 days of age. The bile was exteriorized to exclude the factor of enterohepatic circulation during the experiment. Pharmacokinetic parameters were studied and statistically analyzed after an intravenous single dose of 20 mg/kg of sodium valproate. A significantly (p less than 0.01) longer elimination half-life (t1/2) in guinea pigs less than 10 days of age compared with other groups was observed. Total clearance (Cltot) was significantly smaller (p less than 0.01) in the suckling group than in the juvenile group. Volume of distribution at steady state (Vss) was not significantly different between the suckling and juvenile groups, but was significantly smallest (p less than 0.01) in the adult group. In vitro study showed that the blood-to-plasma concentration ratio, ranging from 0.81 to 0.84, and the plasma unbound fraction (fu), ranging from 0.24 to 0.38, of valproic acid around therapeutic levels (50-100 micrograms/ml) were not significantly different among different age groups. It is obvious that the longer t1/2 in the suckling group is not related to either fu or Vss.(ABSTRACT TRUNCATED AT 250 WORDS)

Age Factors↗

Determination of valproic acid kinetics in patients during maintenance therapy using a tetradeuterated form of the drug.

A method has been developed for measuring concentrations of valproic acid and, with stable isotopes, labelled forms of VPA, in the plasma of patients undergoing maintenance therapy. One tetradeutero isomer of valproic acid-di-(2,3-dideuteropropyl) acetic acid-has been synthesized for administration to patients. A [2H14]valproic acid-diheptadeuteropropyl acetic acid-was synthesized as the internal standard. After isolation from body fluids the acids were methylated with diazomethane. The McLafferty fragments of the methyl esters were used for mass spectrometric quantification. It was demonstrated that the [2H4]valproic acid used behaves kinetically like the unlabelled drug in the human body. One dose of [2H4]valproic acid was given as a pulse dose to epileptic patients and the elimination profile was measured during continuous normal treatment. The half-life of valproic acid in patients under barbiturate or carbamazepine co-medication was reduced to at least half the value found after single dose administration to healthy volunteers.

Epilepsy↗

The effect of hemodialysis and hemoperfusion on serum valproic acid concentration.

We report a patient with dialysis-induced encephalopathy who was taking divalproex sodium for a seizure disorder. Her serum valproic acid concentration appeared to be in the low therapeutic range at 54 mg/l yet she continued to have seizure activity. The elimination half-life and apparent clearance of valproic acid were the same for both a dialysis and nondialysis day, indicating that hemodialysis/hemoperfusion has little effect on the overall removal of valproic acid from the body.

Female↗

Serum lipids, lipoproteins and apolipoproteins A and B in epileptic patients treated with valproic acid, carbamazepine or phenobarbital.

Serum lipids, lipoproteins and apolipoproteins A and B were measured in 101 epileptic patients receiving chronic treatment with valproic acid, carbamazepine or phenobarbital and in 75 age- and sex-matched control subjects. In relation to controls, subjects treated with valproic acid showed significantly lower values of total and LDL-cholesterol levels; subjects treated with carbamazepine showed significantly higher values of HDL-cholesterol and apolipoprotein A concentrations and subjects treated with phenobarbital showed significantly higher values of total cholesterol, HDL-cholesterol, apolipoprotein A and apolipoprotein B levels. The total cholesterol/HDL-cholesterol ratio was significantly lower in patients receiving valproic acid or carbamazepine but not in the phenobarbital-treated group. Changes in serum lipids profile did not correlate with drug plasma concentrations nor the duration of the treatment.

Adolescent↗

Central nervous system manifestations of a valproic acid overdose responsive to naloxone.

We report the case of a 22-year-old man who presented with a depressed level of consciousness after ingesting valproic acid. He responded to IV naloxone; over a nine-hour period, his serum valproic acid level decreased from 180.4 to 59.2 micrograms/ml with multiple-dose charcoal therapy. We recommend the use of both agents in the treatment of valproic acid overdose.

Adult↗